November 15, 2021

Brian C. Moyer, Ph.D.
Director
National Center for Health Statistics
ICD-9-CM Coordination and Maintenance Committee
3311 Toledo Road
Hyattsville, Maryland 20782

Re: Public Comments on the Diagnosis Proposals Presented at the ICD-10 Coordination and Maintenance Committee Meeting on September 13-14, 2021

DELIVERED ELECTRONICALLY VIA nchsicd10CM@cdc.gov

Dear Director Moyer:

The Association for Molecular Pathology (AMP) appreciates the opportunity to comment on the proposed new codes and revisions discussed at the ICD-10 Coordination and Maintenance Committee Meeting on September 13-14, 2021. Specifically, AMP writes to express support for the new ICD-10 code Q85.89 (Other hamartoma syndromes) for Phosphatase and Tensin Homolog (PTEN) Hamartoma Tumor Syndrome.

AMP is an international medical and professional association representing approximately 2,500 physicians, doctoral scientists, and medical technologists who perform or are involved with laboratory testing based on knowledge derived from molecular biology, genetics, and genomics. Membership includes professionals from the government, academic medicine, private and hospital-based clinical laboratories, and the in vitro diagnostics industry.

In accordance with the endorsement from the Centers for Disease Control & Prevention’s Office of Genomics and Precision Public Health, and Division of Cancer Prevention and Control, and the American College of Medical Genetics Genomics (ACMG)¹, AMP supports the new code Q85.89 (Other hamartoma syndromes). We believe the creation of this new code is consistent with current medical practice and will help to foster improved diagnosis, clinical care, and outcomes for patients with PTEN Hamartoma Tumor Syndrome (PHTS).

AMP appreciates your efforts to ensure accurate diagnosis coding and we thank you again for the opportunity to submit comments on the proposed new ICD-10 code Q85.89 (Other hamartoma syndromes). Should you have any questions or require additional information, please direct your correspondence to Tara Burke, Senior Director of Public Policy and Advocacy, at tburke@amp.org.

Sincerely,

Antonia R. Sepulveda, MD, PhD
President, Association for Molecular Pathology